PLYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Polaryx Therapeutics, Inc (PLYX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's focus on rare lysosomal storage disorders, the upcoming SOTERIA trial, and a recent 'Buy' rating with a $10 price target from Maxim indicate strong growth potential. While financials are still in the negative, the significant improvement in net income and EPS suggests progress. The lack of significant trading trends or recent congress trading data does not detract from the long-term potential.
No stock trend data available for technical analysis. Pre-market price is $2.64 with a 0.76% increase, indicating mild positive sentiment.
Maxim's 'Buy' rating with a $10 price target.
Upcoming SOTERIA clinical trial targeting rare lysosomal storage disorders.
FDA's safe-to-proceed letter for PLX-200 clinical development.
No revenue generation yet.
Net income remains negative despite improvements.
Lack of significant trading trends from hedge funds or insiders.
In Q3 2025, revenue remained at $0. Net income improved to -$1,430,000 (up 85.47% YoY). EPS improved to -$0.03 (up 50% YoY). Gross margin remained at 0%.
Maxim initiated coverage on 2026-02-27 with a 'Buy' rating and a $10 price target, citing the differentiated approach of PLX-200 and its potential to address a broad spectrum of lysosomal storage disorders.
